Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 14/20 | 0.73 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.64 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.64 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.64 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.63 |
| ▸ | ALB | P02768 | 2/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GLI1 | P08151 | 1/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.61 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.61 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14628383 | 1.00 | RORC (0.73) | RORCEGLN2EGLN1EGLN3P4HTM | |
| SCHEMBL12557958 | 0.94 | RORC (0.75) | RORCEGLN2EGLN1EGLN3P4HTM | |
| SCHEMBL12558028 | 0.91 | RORC (0.82) | RORCEGLN2EGLN1EGLN3P4HTM | |
| SCHEMBL13628225 | 0.91 | RORC (0.73) | RORCEGLN2EGLN1EGLN3P4HTM | |
| SCHEMBL13628221 | 0.88 | RORC (0.73) | RORCEGLN2EGLN1EGLN3P4HTM | |
| SCHEMBL13637672 | 0.88 | RORC (0.73) | RORCEGLN2EGLN1EGLN3P4HTM | |
| SCHEMBL13628276 | 0.88 | RORC (0.68) | RORCEGLN2EGLN1EGLN3P4HTM | |
| SCHEMBL13628262 | 0.86 | RORC (0.67) | RORCEGLN2EGLN1EGLN3P4HTM | |
| SCHEMBL4445711 | 0.86 | RORC (0.67) | RORCEGLN2EGLN1EGLN3P4HTM | |
| SCHEMBL12558031 | 0.86 | RORC (0.72) | RORCEGLN2EGLN1EGLN3P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144069-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144069-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2011-06-16 | — | — | US | disclosed |
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080207573-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | RORC 41/4885EGLN2 332/4885EGLN1 1102/4885 |
| US-20080207573-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | RORC 41/4885EGLN2 332/4885EGLN1 1102/4885 |
| US-20110144069-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | RORC 41/4885EGLN2 332/4885EGLN1 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.